U.S. Banks Stock News

NYSE:FLR
NYSE:FLRConstruction

Did Winning Donlin Gold’s Feasibility Study Just Shift Fluor’s (FLR) Investment Narrative?

NOVAGOLD Resources and Donlin Gold Holdings recently selected Fluor Corporation to lead the Bankable Feasibility Study for the Donlin Gold project in Alaska, integrating major infrastructure elements such as the power plant, natural gas pipeline, and processing facilities. This mandate places Fluor at the center of engineering work for what is anticipated to become the largest single operating gold mine in the United States, reinforcing its role in complex, cold‑weather mining...
NYSE:KKR
NYSE:KKRCapital Markets

What KKR (KKR)'s Record 2025 Fundraising and Infrastructure Push Means For Shareholders

In early February 2026, KKR & Co. Inc. reported fourth-quarter 2025 revenue of US$5.74 billion and net income of US$1.15 billion, alongside confirming a quarterly dividend of US$0.185 per share payable on March 3, 2026. Management also highlighted a record US$129 billion raised in 2025 and heavy investment across infrastructure and energy transition assets, underscoring the firm’s expanding fee-based platform. We’ll now look at how this record fundraising and infrastructure deployment shape...
NYSE:GOLF
NYSE:GOLFLeisure

Assessing Acushnet Holdings (GOLF) Valuation After Strong Multi‑Period Share Price Momentum

Recent share performance snapshot Acushnet Holdings (GOLF) has caught investor attention after a period of strong stock performance, with the share price at $103.29 and positive returns over the past week, month, past 3 months, year, and 3 and 5 year periods. See our latest analysis for Acushnet Holdings. Looking beyond the recent move, Acushnet’s 30 day share price return of 18.36% and 90 day share price return of 29.06% sit alongside a 1 year total shareholder return of 63.88%. Together,...
NasdaqGS:CBSH
NasdaqGS:CBSHBanks

Assessing Commerce Bancshares (CBSH) Valuation After Its Latest Dividend Increase

Commerce Bancshares (CBSH) has drawn fresh attention after its board declared a quarterly dividend of $0.275 per share, a 5% increase that extends the bank's 58 year streak of annual dividend growth. See our latest analysis for Commerce Bancshares. At a share price of $55.23, Commerce Bancshares has seen firm near term momentum, with a 7 day share price return of 3.06% and a 90 day share price return of 6.80%, even as the 1 year total shareholder return of 12.31% decline shows that longer...
NYSE:SCHW
NYSE:SCHWCapital Markets

A Look At Charles Schwab’s Valuation As Dividend Rises And Leadership Team Is Reorganized

Charles Schwab (SCHW) has put income returns and leadership structure in focus, with the board lifting the regular quarterly common dividend to US$0.32 per share and reshaping senior roles around technology, operations, and wealth services. See our latest analysis for Charles Schwab. These dividend moves and refreshed leadership come as Charles Schwab’s share price sits at US$107.21, with a 30-day share price return of 7.03% and a 1-year total shareholder return of 30.44%, suggesting momentum...
NasdaqGS:ARQT
NasdaqGS:ARQTBiotechs

Why Arcutis Biotherapeutics (ARQT) Is Up 5.1% After Positive Infant Atopic Dermatitis Trial Results And What's Next

Arcutis Biotherapeutics recently reported positive topline results from its INTEGUMENT-INFANT Phase 2 trial, showing ZORYVE cream 0.05% was well tolerated and improved atopic dermatitis in infants aged 3 months to under 24 months, with low rates of mostly mild to moderate side effects. By reinforcing a consistent safety and efficacy profile for ZORYVE in very young children, these data may broaden its potential treatment reach within pediatric dermatology. We’ll now examine how this...
NYSE:LEVI
NYSE:LEVILuxury

Levi Strauss (LEVI) Is Up 9.8% After 2025 Earnings Beat And New Global Brand Campaign Launch

Levi Strauss & Co. recently reported full-year 2025 results showing higher sales of US$6.28 billion and net income of US$578.1 million, declared a US$0.14 per-share dividend, completed a multi-year share repurchase program, and saw director Christopher McCormick announce his planned retirement at the 2026 annual meeting. At the same time, the company launched its “Behind Every Original” global campaign with a high-profile Super Bowl spot, underlining Levi’s emphasis on brand storytelling and...
NYSE:BIO
NYSE:BIOLife Sciences

Is AOAC Validation Of EZ-Check Listeria Kits Altering The Investment Case For Bio-Rad Laboratories (BIO)?

Bio-Rad Laboratories recently received AOAC International validation for its EZ-Check Listeria spp. Kit and EZ-Check Listeria monocytogenes Kit, which are designed to detect Listeria in food and environmental samples using multiplex amplification and internal controls. This third-party validation underscores Bio-Rad’s role in supplying workflow-friendly food safety diagnostics, potentially increasing confidence and adoption among testing laboratories and industrial quality-control...
NasdaqGM:ENPH
NasdaqGM:ENPHSemiconductor

Why Enphase Energy (ENPH) Is Up 34.9% After Q4 Earnings, EV Platform Progress And Buybacks

Enphase Energy reported past fourth-quarter 2025 results showing quarterly sales of US$343.32 million and net income of US$38.71 million, alongside full-year 2025 revenue of US$1.47 billion and net income of US$172.13 million, and issued first-quarter 2026 revenue guidance of US$270.0 million to US$300.0 million. The company also highlighted progress on its IQ Bidirectional EV Charging Platform and completed a US$731.34 million share repurchase program covering 8,869,963 shares. Against this...
NYSE:ZBH
NYSE:ZBHMedical Equipment

Should Zimmer Biomet’s (ZBH) Consistent Revenue Outperformance Shape Investor Expectations For This Earnings Release?

Zimmer Biomet Holdings recently reported that it will release its upcoming earnings results, with analysts expecting revenue of about US$2.22 billion, reflecting year-on-year growth of 9.9% and an improvement from the 4.3% increase recorded in the same quarter a year earlier. An interesting angle is that Zimmer Biomet has missed Wall Street’s revenue estimates only once in the past two years, typically outperforming consensus by an average of 0.7%, which may be influencing how investors...
NYSE:TEVA
NYSE:TEVAPharmaceuticals

Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Recent Share Price Momentum And Biosimilar Growth Hopes

Why Teva Pharmaceutical Industries (NYSE:TEVA) is on investors’ radar today Teva Pharmaceutical Industries (NYSE:TEVA) has drawn fresh attention after recent share price moves, with the stock showing mixed short term returns but a stronger gain over the past 3 months. See our latest analysis for Teva Pharmaceutical Industries. While the latest 1 day share price return of 0.63% and 7 day return of 2.96% show some cooling at a recent price of US$34.47, the 90 day share price return of 37.17%...
NYSE:FLS
NYSE:FLSMachinery

Flowserve (FLS) Is Up 8.1% After Mixed 2025 Results And Trillium Deal - Has The Bull Case Changed?

Flowserve Corporation recently reported fourth-quarter and full-year 2025 results showing higher sales but a quarterly net loss, while issuing 2026 guidance calling for modest organic and total sales growth. The company also outlined longer-term margin ambitions and highlighted opportunities in nuclear and power markets, supported by the planned US$490.00 million acquisition of Trillium Flow Technologies’ valves division. We’ll now examine how Flowserve’s improved margin trajectory and 2026...
NasdaqGS:EXE
NasdaqGS:EXEOil and Gas

A Look At Expand Energy (EXE) Valuation As Leadership Changes And Headquarters Move Proceed

Expand Energy (EXE) is entering a transition period, with Chairman Michael Wichterich stepping in as Interim President and CEO while the company prepares to shift its headquarters from Oklahoma City to Houston. See our latest analysis for Expand Energy. The recent headquarters move and leadership reshuffle come as the stock trades at US$103.24. The 1 day share price return shows a 6.46% decline and the 90 day share price return shows a 12.98% decline, while the 5 year total shareholder return...
NYSE:CNS
NYSE:CNSCapital Markets

A Look At Cohen & Steers (CNS) Valuation After AUM Growth And Resilient Earnings

Latest AUM update and earnings context Cohen & Steers (CNS) reported preliminary assets under management of US$93.1b as of January 31, 2026, tied to market appreciation and net inflows, alongside ongoing revenue growth and maintained profitability, despite earnings that were slightly below forecast. See our latest analysis for Cohen & Steers. At a share price of US$64.30, Cohen & Steers has seen a 2.54% 1 day share price return and a modest 0.97% 7 day share price return. Its 1 year total...